House Dust Mite Allergy Market Overview, Recent Development,Pipeline Review 2019

Posted by Deeksha on September 30th, 2019

The global market status for House Dust Mite Allergy is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “House Dust Mite Allergy-Pipeline Review, H2 2019”, which tends to deliver in-depth knowledge associated to the House Dust Mite Allergy for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market size, revenue and geography; making it quite useful for the readers.

Get Sample Copy at https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519466

House Dust Mite Allergy - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2019, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 1, 4 and 1 respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key company’s involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

Browse Complete Report at https://www.marketresearchhub.com/report/house-dust-mite-allergy-pipeline-review-h2-2019-report.html

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy - Overview
House Dust Mite Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
House Dust Mite Allergy - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
House Dust Mite Allergy - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergy Therapeutics Plc
Anergis SA
ASIT Biotech SA
Astellas Pharma Inc
Biomay AG
Genetic Immunity Inc
Roxall Medizin GmbH
Stallergenes Greer plc
House Dust Mite Allergy - Drug Profiles
Allergan for Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Asthma and House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-2390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clustoid d. pteronyssinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DermAll-HDM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hdm-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-103 - Drug Profile
Product Description
Mechanism Of Action

Continued………..#@